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Abstract: Astaxanthin, a red C40 carotenoid, is one of the most abundant marine carotenoids.
It is currently used as a food and feed additive in a hundred-ton scale and is furthermore an
attractive component for pharmaceutical and cosmetic applications with antioxidant activities.
Corynebacterium glutamicum, which naturally synthesizes the yellow C50 carotenoid decaprenoxanthin,
is an industrially relevant microorganism used in the million-ton amino acid production. In this work,
engineering of a genome-reduced C. glutamicum with optimized precursor supply for astaxanthin
production is described. This involved expression of heterologous genes encoding for lycopene
cyclase CrtY, β-carotene ketolase CrtW, and hydroxylase CrtZ. For balanced expression of crtW
and crtZ their translation initiation rates were varied in a systematic approach using different
ribosome binding sites, spacing, and translational start codons. Furthermore, β-carotene ketolases
and hydroxylases from different marine bacteria were tested with regard to efficient astaxanthin
production in C. glutamicum. In shaking flasks, the C. glutamicum strains developed here overproduced
astaxanthin with volumetric productivities up to 0.4 mg¨L´1¨h´1 which are competitive with current
algae-based production. Since C. glutamicum can grow to high cell densities of up to 100 g cell dry
weight (CDW)¨L´1, the recombinant strains developed here are a starting point for astaxanthin
production by C. glutamicum.
Keywords: astaxanthin production; carotenoids; genome-reduced Corynebacterium glutamicum;
systematic approach; metabolic engineering
1. Introduction
Carotenoids are natural pigments with yellow-to-red coloring properties, found ubiquitously in
plants, algae, fungi, and bacteria. These pigments form a subfamily of the large and diverse group of
terpenoids with more than 55,000 different structures. Terpenoids are natural secondary metabolites
composed of isoprene units, which typically exhibit flavoring, fragrance and coloring properties.
Carotenoids and their derivatives have become more and more important for the health care industry
due to their beneficial effects on human and animal health and their possible pharmaceutical, medical,
and nutraceutical applications. For example, carotenoids are suggested to have beneficial effects on the
human immune system and to protect against degenerative diseases and cancer [1–3]. Astaxanthin is
a marine, red, cyclic C40 carotenoid and the third most important carotenoid on the global market
after β-carotene and lutein, with a predicted sales volume of 670 metric tons valued at 1.1 billion US$
in 2020 [4]. Currently, astaxanthin is primarily used as a food and beverage colorant, in animal feed
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and in nutraceuticals [5] with e.g., an annual demand of 130 tons for coloration of poultry, salmon,
lobster and fish [6]. Astaxanthin shows the strongest hitherto demonstrated anti-oxidant effect due to
its keto and hydroxy groups at 4,4'- and 3,3'-beta-ionone ring positions, respectively. Those functional
groups result in a more polar nature of astaxanthin and explain its unique antioxidative properties [7].
Furthermore, astaxanthin can be esterified which leads to increased stability [8]. Therefore, the demand
for astaxanthin is particularly rising in the health sector [5]. Astaxanthin has been described to promote
skin health and to have potential anti-aging effect [9]. Moreover, it alleviates the fatigue, inflammation,
and aging of the eye [10–12]. Astaxanthin has a positive effect on blood rheology and potential
antihypertensive properties, which makes it interesting for therapy of cardiovascular diseases [13,14].
Its wide potential for the reduction of inflammation also promotes the immune system functions [15].
In addition, astaxanthin was reported to have a positive impact on muscle recovery when used as a
nutritional supplement [16].
Although the chemical synthesis of astaxanthin from petrochemical precursors is so far more
cost-efficient and therefore dominates the market [17], consumer demand for naturally produced
carotenoids is increasing [18]. Synthetic astaxanthin is often a mixture of R- and S-enantiomers and,
thus, inferior to natural-based astaxanthin [19] and not suitable as a neutraceutical supplement without
further complex and cost-intensive purification steps before application. Consequently, the demand
for an efficient, environmentally friendly production of natural astaxanthin, and carotenoids in general,
by microbial hosts is on the rise [20–22].
C. glutamicum is a Gram-positive soil bacterium with a long biotechnological history: its relevance
goes back to the 1950s when it was first discovered as a natural glutamate producer [23]. Over centuries
it has been used for the million-ton scale production of different amino acids for the feed and food
industry. Moreover, its potential for biotechnological application has been further exploited [24]:
besides amino acids, e.g., diamines [25], alcohols [26], and terpenoids [27,28] can be produced by
engineered C. glutamicum. This bacterium has the ability to grow aerobically on a variety of carbon
sources like glucose, fructose, sucrose, mannitol, propionate, and acetate [29,30]. In addition, it has
been engineered to grow with alternative carbon sources such as glycerol [31], pentoses [32], amino
sugars [33,34], β-glucans [35], and starch [36]. C. glutamicum is pigmented due to synthesis of the C50
carotenoid decaprenoxanthin and its glucosides. Its potential to produce carotenoids has been explored
over recent years [28,37–39]. The carotenogenic pathway of C. glutamicum was identified [40] and
several metabolic engineering strategies were applied to convert this biotechnologically established
bacterium into a carotenoid producer [41,42].
In order to enable C40 carotenoid production by C. glutamicum, the conversion of lycopene to
decaprenoxanthin needs to be prevented by deletion of the genes encoding lycopene elongase and
ε-cyclase. As consequence of deletion of the lycopene elongase encoding gene crtEb, the cells exhibited
a slight red color due to accumulation of the intermediate lycopene [37]. Additional overexpression
of the endogenous genes crtE, crtB, and crtI in C. glutamicum ∆crtEb intensified the red phenotype
as conversion of GGPP to the red chromophore lycopene was improved. Thereby, the lycopene
content could be increased 80 fold with 2.4 ˘ 0.3 mg¨ (g¨CDW)´1 and showed for the first time
enhanced C40 carotenoid production in C. glutamicum [37]. Heterologous expression of crtY from
Pantoea ananatis (crtYPa) in a lycopene accumulating platform strain led to the production of the orange
pigment β-carotene. Zeaxanthin was accumulated when crtZ from P. ananatis (crtZPa) was expressed
in addition [38]. Furthermore, carotenoid biosynthesis was improved by enhancing the precursor
supply, which was accomplished by overexpression of the dxs gene encoding the enzyme for the initial
condensation of pyruvate and GAP in the MEP-pathway [42].
In this study production of the marine carotenoid astaxanthin by C. glutamicum was developed
using a β-carotene producing strain (Figure 1). Two strategies were followed: (i) the implementation
of a combinatorial gene assembly for crtWBa and crtZPa to optimize the ratio of enzyme quantities
(ketolase and hydroxylase) by variation of translation initiation rates (TIR) based on different ribosome
binding sites, spacing lengths, and translation start codons and (ii) the use of alternative crtW and crtZ
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genes from marine and non-marine prokaryotes in a two-vector system in order to find enzymes with
higher activities or affinities for the intermediates of the astaxanthin biosynthesis pathway (Figure 1).
Combined expression of crtW and crtZ from the marine bacterium Fulvimarina pelagi yielded a
C. glutamicum strain producing astaxanthin as the major carotenoid in shaking flasks with productivities
of up to 0.35 mg¨L´1¨h´1.
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Figure  1.  Scheme  of  C40  cyclic  carotenoid  biosynthesis  in  recombinant  C.  glutamicum.  The 
biosynthesis  of  C40  cyclic  carotenoids  derived  from  precursor  molecules  dimethylallyl 
pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) is illustrated. Genes are shown next 
to the reaction catalyzed by the encoded enzyme (crtE: Prenyl transferase, crtB: Phytoene synthase, 
crtI:  Phytoene  desaturase,  crtEb:  Lycopene  elongase,  crtYe/f:  C45/50  carotenoid  ε‐cyclase,  crtY: 
Lycopene  β‐cyclase,  crtZ:  β‐Carotene  hydroxylase  (3,3ʹ‐beta‐ionone  ring  hydroxylase),  crtW:  β‐
Carotene ketolase (4,4ʹ‐beta‐ionone ring ketolase). Endogenous genes are shown in grey boxes and 
their overexpression indicated by green arrows. Heterologous genes are highlighted in colored boxes. 
2. Results 
2.1. Construction of a β‐Carotene Producing C. glutamicum Base Strain 
C. glutamicum was metabolically engineered for plasmid‐independent lycopene overproduction 
(Table  1).  Chromosomal  integration  of  the  synthetic  operon  crtEBI  under  the  control  of  the 
endogenous promoter of the gene coding for the translational elongation factor (Ptuf) in the crtYeYfEb 
deletion mutant  of  C.  glutamicum MB001  (LYC3)  [37]  was  performed  in  order  to  improve  the 
expression  of  prenyltransferase  CrtE,  phytoene  synthase  CrtB  and  phytoene  desaturase  CrtI 
encoding genes. Thereby, the flux from the precursor molecules IPP and DMAPP to lycopene was 
enhanced and an 8‐fold higher lycopene titer resulted for strain LYC4. When dxs, encoding the first 
enzyme  of  the MEP‐pathway, was  additionally  overexpressed  by  chromosomal  exchange  of  its 
natural promoter by the strong promoter Ptuf, the lycopene titer was further improved by 34% and 
the respective strain LYC5 produced 0.43 ± 0.02 mg∙(g∙CDW)−1 (Table 1). 
Table 1. Lycopene production by plasmid‐free recombinant C. glutamicum strains. Cells were grown 
in glucose CGXII minimal medium for 24 h. Means and standard deviations of three replicates are 
given. 
Name  Strain Lycopene (mg∙(g∙CDW)−1)
LYC3  crtYeYfEb deletion mutant of C. glutamicum MB001 0.04 ± 0.01 
LYC3‐Ptufdxs  LYC3::Ptufdxs  0.09 ± 0.01 
LYC4  LYC3::PtufcrtEBI  0.32 ± 0.01 
LYC5  LYC4::Ptufdxs  0.43 ± 0.02 
Figure 1. Scheme of C40 cyclic carotenoid biosynthesis in recombinant C. glutamicu . The biosynthesis
of C40 cyclic carotenoids derived from precursor molecules dimethylallyl pyrophosphate (DMAPP)
and isopentenyl pyrophosphate (IPP) is illustrated. Genes are shown next to the reaction catalyzed by
the encoded enzyme (crtE: Prenyl transferase, crtB: Phytoene synthase, crtI: Phytoene desaturase, crtEb:
Lycopene elongase, rtYe/f : C45/50 carotenoid ε-cyclase, crtY: Lycopene β-cyclase, rtZ: -Carotene
hydroxylase (3,3'-beta-ionone ring hydroxylase), crtW: β-Carotene ketolase (4,4'-beta-ionone ring
ketolase). Endogenous genes are shown in grey boxes and their overexpression indicated by green
arrows. Heterologous genes are highlighted in colored boxes.
2. Results
2.1. Construction of a β-Carotene Producing C. glutamicum Base Strain
C. glutamicum w s metabolically engineered for plasmid-independent lyc pene overproduction
(Table 1). Chromosomal integration of the synthetic operon crtE I under the control of the endogenous
promoter of the gene coding for the translational elongation factor (Ptuf) in the crtYeYfEb deletion
mutant of C. glutamicum MB001 (LYC3) [37] was performed in order to improve the expression
of prenyltr nsferase CrtE, phyt ene syn hase CrtB and phytoene desaturase CrtI enco ing genes.
Thereby, the flux from the precursor molecules IPP and DMAPP to lycopene was enhanced and an
8-fold higher lycopene titer resulted for strain LYC4. When dxs, encoding the first enzyme of the
MEP-pathway, was additionally overexpressed by chromosomal exchange of its natural promoter by
the strong promoter Ptuf, the lycopene titer was further improved by 34% and the respective strain
LYC5 produced 0.43 ˘ 0.02 mg¨ (g¨CDW)´1 (Table 1).
Table 1. ycopene production by plasmid-free recombinant C. glutamicum strains. Cells were grown in
glucose CGXII minimal medium for 24 h. Means and standard deviations of three replicates are given.
Name Strain Lycopene (mg¨ (g¨CDW)´1)
LYC3 crtYeYfEb deletion mutant of C. glutamicumMB001 0.04 ˘ 0.01
LYC3-Ptufdxs LYC3::Ptufdxs 0.09 ˘ 0.01
LYC4 LYC3::PtufcrtEBI 0.32 ˘ 0.01
LYC5 LYC4::Ptufdxs 0.43 ˘ 0.02
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Strain LYC5 was converted to a β-carotene producing strain (Table 2) by heterologous expression
of the lycopene β-cyclase gene crtY from P. ananatis. Plasmid-borne expression of crtY under the
control of the isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible tac promoter (pEKEx3_crtYPa)
allowed for β-carotene production. Constitutive expression of crtY under control of the Ptuf promoter
from the newly constructed expression and shuttle vector pSH1 resulted in a comparable production
titer. Similarly, a β-carotene titer of 6.5 mg¨ g´1 was achieved by BETA3, a strain having crtYPa under
the control of Ptuf integrated into the genome of C. glutamicum strain LYC5 (Table 2).
Table 2. β-Carotene production in recombinant C. glutamicum strains. Cells were grown in glucose
CGXII minimal medium for 24 h induced by 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).
Means and standard deviations of three replicates are given.
Name Strain β-Carotene (mg¨ (g¨CDW)´1)
BETA1 LYC5 (pEXEx3_crtYPa) 5.2 ˘ 1.0
BETA2 LYC5 (pSH1_crtYPa) 5.9 ˘ 0.8
BETA3 LYC5::Ptuf_ crtYPa 6.5 ˘ 1.3
2.2. Design of the Combinatorial Gene Assembly and Library Construction for Engineering Astaxanthin
Production in C. glutamicum
Metabolic flux in a synthetic pathway may require well-adjusted activities of the enzymes
involved. Prediction of the flux from gene expression is rather difficult, hence, a combinatorial
gene assembly was used to screen for balanced expression of the β-carotene ketolase and β-carotene
hydroxylase encoding genes with respect to astaxanthin production. Since crtY from P. ananatis has
previously been expressed successfully in C. glutamicum for production of β-carotene, the β-carotene
hydroxylase crtZ gene from this organism was chosen. However, P. ananatis lacks β-carotene ketolase,
and therefore the β-carotene ketolase gene crtW from Brevundimonas aurantiaca was used, which on
the contrary lacks a crtZ gene. CrtW from B. aurantiaca and crtZ from P. ananatis were combined in an
artificial operon under the control of the constitutive Ptuf promoter in the vector pSH1. Gene expression
was varied by combining different ribosome-binding sites (RBS) and start codons separated by
spacers of different lengths (Figure 2). The theoretical translation initiation rates were calculated
using the RBS calculator [43] and ranged from 14 to 33,626 for crtW and from 40 to 30,731 for crtZ.
A library of combinatorially assembled crtW and crtY genes was generated and the constructed
library of pSH1_crtWBa_crtZPa plasmids was used to transform the β-carotene accumulating strain
C. glutamicum BETA1.
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Figure 2. Combinatorial gene as e bl f slation initiation of β-carotene ketolase and
hydroxylase genes. i i s f i ferent RBS sequences (diff rences given in red l tters),
translation start codons (ATG/GTG) a s c rs ( , or 8 bp in length) between them are highlighted
in a green box.
Mar. Drugs 2016, 14, 124 5 of 21
For each gene four different RBS, three different spacer lengths, and two different translational
start codons were chosen. These were introduced by the forward primers and equimolar mixture of
these primers and one reverse primer by PCR. The resulting DNA products were gel-extracted and
combined by cloning via Gibson Assembly [44] in pSH1. Thus, theoretically 24 different constructs
per gene resulted (Figure 2). With this approach 576 different combinations of crtW and crtZ
genes are theoretically possible and the event of creating a specific combination of the two genes
follows the Poisson distribution [45] with a probability of 1/576 (Equation (1)). To cover with 99%
probability that a single specific combination is present at least once in the library, approximately
2650 clones are required (Equation (1)). The necessary number of transformants for creating a library
with each of the 576 combinations can be calculated employing the path rules [45]. For creating
a library that includes each of the 576 specific combinations at least once with a 99% probability,
approximately 6315 transformants are required (Equation (2)). Preliminary experiments showed that
correct assembling of an insert with the restricted vector via Gibson assembly occurs in about 90% of
the events. Consequently, the number of transformants had to be corrected by multiplication by 1.11,
thus, a minimum of 7000 transformants had to be screened.
pλ pkq “ λ
k
k!
˚ e´λ (1)
Equation (1): Poisson distribution. λ = n * p; n: library size; p: probability of one specific gene
assembly of crtW and crtZ, k: number of one specific gene assembly in library with size n.
pall pk ě 1q “
´
1´ e´λ
¯N
(2)
Equation (2): Path rules. λ = n * p; n: library size; p: probability of one specific gene assembly of
crtW and crtZ, k: number of one specific gene assembly in library with size n; N: number of possible
gene assemblies.
Around 8000 transformants were visually color-screened on plates and 46 colonies with different
colors ranging from yellow to red were selected for further analysis. The plasmid DNA was isolated
and sequenced to identify the sequences (RBS, spacer, translational start codon) of crtW and crtZ.
The set of 46 transformants represented 20 of the 24 possible variants for crtW and 19 of 24 variants of
crtZ. Furthermore, three plasmids harbored only the crtW gene and two plasmids harbored only the
crtZ gene.
2.3. Combinatorial Engineering Covered Vastly Different Astaxanthin, β-Carotene, Zeaxanthin and
Canthaxanthin Titers
To evaluate which of the gene combinations was best in terms of astaxanthin production, the
46 selected transformants referred to as COMB strains, were characterized with respect to carotenoid
production. After growth in CGXII minimal medium with 100 mM glucose, appropriate antibiotics
and 1 mM IPTG in a Biolector micro fermentation system (Figure 3), carotenoids were quantified by
HPLC using standards for β-carotene, canthaxanthin, zeaxanthin, and astaxanthin.
As expected, the parental strain BETA1 (Figure 3) produced β-carotene (6.7 mg¨ (g¨CDW)´1),
but no further carotenoids. The 46 COMB strains could be categorized in six groups according to
their carotenoid production profiles (group I: only lycopene, group II: only β-carotene, group III:
β-carotene and zeaxanthin, group IV: β-carotene, zeaxanthin and astaxanthin, groupV: β-carotene
and canthaxanthin, group VI: β-carotene, canthaxanthin and astaxanthin; Figure 4). For all COMB
strains, the TIRs were calculated with the RBS calculator tool [41], which takes (amongst others) the
free binding energy of the RBS and the 16S rRNA into consideration as well as the free energy of
secondary structures of the mRNA itself.
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Figure 3. COMB strains expressing crtW from B. aurantiaca and crtZ from P. ananatis with varied
translation initiation signals after growth in the Biolector micro fermentation system. Color phenotypes
of 46 different COMB strains and the parental strain BETA1 (bottom right) after 24 h of cultivation.
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COMB 40 (Figure 4) produced none of the cyclic carotenoids, but about as much lycopene
(0.39 mg¨ (g¨CDW)´1) s LYC5 (0.5˘ 0.1 mg¨ (g¨CDW)´1), the parental strai of BETA1. S quencing of
pEKEx3_crtYPa isolated from COMB 40 revealed a deletion of 11 base pairs in the coding region of
crtY, hence, β-carotene production was not possible in this strain. By contrast, the other 45 strains
produced β-carotene with a titer of at least 1 mg¨ (g¨CDW)´1 (Figure 4). For about 24% of the strains,
β-carotene was the only cyclic carotenoid being produced. In these cases, the calculated TIRs of
crtW and/or crtZ were rather low (less than 200 for at least one gene; Figure 4). Zeaxanthin, one of
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the intermediates in the pathway towards astaxanthin, was detected in only four strains (COMB 14,
COMB 26, COMB 30, and COMB 35) and these strains exhibited very diverse TIRs for crtZ (from
81 to 5887) (Figure 4). The highest production of zeaxanthin was detected in group IV for strain
COMB 30 with 0.3 mg¨ (g¨CDW)´1, although this strain possessed a low TIR for crtZ. The highest
titers of canthaxanthin and astaxanthin were observed among the strains of the large group VI
(39%) and these strains co-produced β-carotene along with canthaxanthin and astaxanthin (Figure 4).
The intermediate canthaxanthin was detected in 30 strains with strain COMB 42 showing the highest
titer for canthaxanthin (0.6 mg¨ (g¨CDW)´1; Figure 4). In average, the TIR for crtW of these strains
was high (10,299). Astaxanthin was identified in 20 of the 46 strains, but only two strains, COMB
44 and COMB 48, exhibited reasonably high astaxanthin yields (approximately 0.3 mg¨ (g¨CDW)´1).
These two strains exhibited high crtW TIRs (33,626) and medium to high crtZ TIRs (5813 and 1377)
(Figure 4).
In general, it was found that the higher the TIR of crtW the higher was the astaxanthin production,
with three exceptions, COMB 11, COMB 12, and COMB 45 (Figure 4). In the latter three strains,
however, the TIRs for crtZ were 3 to 145-fold lower than in the best astaxanthin producing strains
COMB 44 and COMB 48. For strains COMB 44 and COMB 48, a spacing length of six base pairs, the
RBS sequence GAAAGGAGG, and the translation start codon ATG was found for crtW. The crtZ gene
in COMB 44 showed the consensus RBS sequence, a spacer length of eight base pairs and ATG as
translational start codon. The crtZ gene variant of COMB 48 had a slightly lower TIR and possessed
the RBS sequence GAAAGAAGG, six base pairs of spacing and ATG as start codon.
Three strains (COMB 37, COMB 3 and COMB 19) did not express crtZ due to an incorrect
gene assembly. Strains COMB 3 and COMB 19 accumulated canthaxanthin besides β-carotene,
while COMB 37, which also showed a low TIR for crtW, only accumulated β-carotene (Figure 4).
Strains COMB 25 and COMB 14 did not express crtW due to an incorrect gene assembly. While COMB
25 only produced β-carotene probably because of a very low TIR for crtZ (Figure 4), strain COMB 14
produced zeaxanthin besides β-carotene.
Taken together, widely varied carotenoid production was represented by the library, but none of
the combinations tested yielded high astaxanthin product levels.
2.4. In Silico Analysis of the Carotenogenic Genes crtZ and crtW from Marine and Non-Marine Bacteria for
Heterologous Expression in C. glutamicum
In the above described experiments the bacteria B. aurantiaca and P. ananatis were chosen as sources
for crtW and crtZ, respectively, although not producing astaxanthin themselves. B. aurantiaca lacks crtZ,
but possesses the crtG gene coding for a 2,2'-beta-ionone ring hydroxylase and produces canthaxanthin
and 2-hydroxycanthaxanthin as main carotenoids. P. ananatis lacks crtW and produces glycosylated
zeaxanthin involving CrtZ. Thus, on the basis of available genome sequences, reported carotenoid
production and biological diversity, four alternative prokaryotic natural carotenoid producers were
selected as donors for crtW and crtZ. Since crt genes of Brevundimonas species were reported to show
a high potential for heterologous carotenoid productions [47] two different Brevundimonas strains
were selected: Brevundimonas vesicularis, a non-marine bacterium suggested to be a suitable gene
donor for astaxanthin production [47,48], and as alternative Brevundimonas bacteroides [49]. The marine
bacterium Fulvimarina pelagi was chosen due to its promising brownish-yellow color as a consequence
of carotenoid accumulation [50] and the evolutionary distance to Brevundimonas. In addition, the
red-pigmented marine bacterium Sphingomonas astaxanthinifaciens was selected since experimental
evidence that astaxanthin is the major carotenoid produced by this bacterium has been reported [51,52].
The organization of carotenogenic gene clusters of the considered donors B. aurantiaca,
B. bacteroides, B. vesicularis, F. pelagi, P. ananatis, and S. astaxanthinifaciens was analyzed on the basis
of the partly available genome sequences/contigs or scaffolds in GenBank: the carotenoid gene
cluster of B. bacteroides, an orange-red pigmented bacterium, comprises crtW and crtZ as well as
the gene idi encoding the IPP isomerase of the MEP-pathway and several other genes encoding for
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enzymes of the astaxanthin biosynthesis pathway, however, a crtE gene is not present in its genome.
The genome of B. vesicularis DC263, a red-pigmented soil bacterium, possesses a large carotenoid gene
cluster with 10 coding sequences, eight of which encode enzymes for the biosynthesis pathway of
astaxanthin or the terpenoid precursors IPP and DMAPP. In addition, a second hydroxylase CrtG is
encoded, which is responsible for further hydroxylation of astaxanthin leading to 2-hydroxyastaxanthin.
Carotenogenic genes of F. pelagi, a Mn(II)-oxidizing bacterium [53], are found in at least four different
loci of the genome. Genes encoding for enzymes of the astaxanthin biosynthesis and glycosylation
as well as enzymes for the spirilloxanthin biosynthesis (CrtC, CrtD, CrtF) are present. Furthermore,
two genes coding for an ABC-transporter and a MFS-transporter are located next to the carotenogenic
genes crtZ and crtY. S. astaxanthinifaciens, producing astaxanthin and its glycosides, has at least two
carotenoid gene clusters in its genome also including farnesyl pyrophosphate synthase. Moreover, a
gene encoding a putative carotenoid transporter is located in this cluster.
2.5. High Astaxanthin Production by C. glutamicum Strains Expressing crtW and crtZ from F. pelagi
β-Carotene ketolase and hydroxylase genes (crtW and crtZ, respectively) from B. aurantiaca,
B. bacteroides, B. vesicularis, F. pelagi, P. ananatis, and S. astaxanthinifaciens were expressed in the
plasmid-free β-carotene overproducing C. glutamicum strain BETA4. The affinities of the β-carotene
ketolases and hydroxylases for the various substrates and intermediates of the branched astaxanthin
biosynthesis pathway may vary and it is conceivable that astaxanthin production proceeds e.g., only
via canthaxanthin or only via zeaxanthin. However, also various other routes via hydroxyechinenone
are possible (Figure 1). Thus, in a first step only either crtW or crtZ was expressed in the parental
strain BETA4 that produced ~12 mg¨ (g¨CDW)´1 β-carotene with a productivity of ~3.4 mg¨L´1¨h´1
in 24 h of cultivation and a growth rate of 0.32 ˘ 0.01 h´1. Zeaxanthin accumulated (0.52 and
1.1 mg¨ (g¨CDW)´1, respectively) when crtZ from P. ananatis or F. pelagi were expressed (data not
shown). Canthaxanthin accumulated (0.34 to 1.0 mg¨ (g¨CDW)´1) when crtW from S. astaxanthinifaciens,
F. pelagi or B. aurantiaca were expressed, while only traces were observed as consequence of expression
of crtW from B. bacteroides or B. vesicularis (data not shown). Thus, crtW from S. astaxanthinifaciens,
F. pelagi or B. aurantiaca and crtZ from P. ananatis or F. pelagi appeared suitable for further analysis.
Subsequently, combinations of crtW from S. astaxanthinifaciens and B. aurantiaca with crtZ from
F. pelagi were co-expressed in strain BETA4 using the two expression vectors pSH1 and pEC-XT99A.
In addition, the crtW and crtZ genes from species known to synthesize astaxanthin (B. bacteroides,
B. vesicularis, F. pelagi, and S. astaxanthinifaciens) were co-expressed in BETA4. Carotenoids of
these strains were extracted and analyzed in the stationary growth phase 24 h after inoculation.
Transformants harboring the genes from B. vesicularis grew poorly and were not analyzed further.
Co-expression of crtW and crtZ from B. bacteroides and crtW and crtZ from S. astaxanthinifaciens
genes led to less than 0.1 mg¨ (g¨CDW)´1 of astaxanthin (Table 3). Strains expressing crtZ from
F. pelagi in combination with crtW from S. astaxanthinifaciens, B. aurantiaca, and F. pelagi produced
about 0.7, 1.7 and 1.6 mg¨ (g¨CDW)´1 of astaxanthin, respectively (Table 3). In all strains except
for BETA4(pSH1_crtWFp)(pEC-XT_crtZFp), β-carotene was the major carotenoid (~2 mg¨ (g¨CDW)´1).
C. glutamicum BETA4 co-expressing crtW and crtZ from F. pelagi (subsequently named ASTA1) produced
astaxanthin as main carotenoid (1.6 ˘ 0.3 mg¨ (g¨CDW)´1) and accumulated little canthaxanthin and
β-carotene (0.1 ˘ 0.1 and 0.3 ˘ 0.1 mg¨ (g¨CDW)´1, respectively) as side products (Table 3). This strain
produced astaxanthin with a volumetric productivity of 0.4 ˘ 0.1 mg¨L´1¨h´1 in shaking flasks with a
growth rate of 0.29 ˘ 0.05 h´1.
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Table 3. Astaxanthin, canthaxanthin, and β-carotene production by strains overexpressing
various combinations of crtW and crtZ genes. Titers, productivities, and final ODs are given
as means and standard deviations (n = 3) after 24 h of cultivation in CGXII + 100 mM
glucose. B.a.: Brevundimonas aurantiaca; B.b.: Brevundimonas bacteroides; F.p.: Fulvimarina pelagi;
S.a.: Sphingomonas astaxanthinifaciens.
Strain Growth Carotenoid Titer (mg¨g´1¨CDW) Volumetric Productivity (mg¨L´1¨h´1)
BETA4
Transformed with
Final
OD600 nm
Astaxanthin Canthaxanthin β-Carotene Astaxanthin Canthaxanthin β-Carotene
- 28 ˘ 1 <0.1 <0.1 11.7 ˘ 2.0 <0.1 <0.1 3.4 ˘ 0.5
(pSH1_crtWBb)
(pEC-XT_crtZBb)
21 ˘ 1 <0.1 <0.1 4.9 ˘ 0.4 <0.1 <0.1 1.1 ˘ 0.1
(pSH1_crtWSa)
(pEC-XT_crtZSa)
22 ˘ 2 < 0.1 0.3 ˘ 0.1 3.3 ˘ 0.5 <0.1 <0.1 0.8 ˘ 0.1
(pSH1_crtWSa)
(pEC-XT_crtZFp)
24 ˘ 1 0.7 ˘ 0.3 0.2 ˘ 0.1 1.8 ˘ 0.1 0.2 ˘ 0.1 <0.1 0.5 ˘ 0.1
(pSH1_crtWBa)
(pEC-XT_crtZFp)
22 ˘ 1 1.7 ˘ 0.3 0.1 ˘ 0.1 2.0 ˘ 0.5 0.4 ˘ 0.1 <0.1 0.4 ˘ 0.2
(pSH1_crtWFp)
(pEC-XT_crtZFp)
= ASTA1
23 ˘ 1 1.6 ˘ 0.3 0.1 ˘ 0.1 0.3 ˘ 0.1 0.4 ˘ 0.1 <0.1 0.1 ˘ 0.1
3. Discussion
In this study, Corynebacterium glutamicum was engineered for the production of the marine
carotenoid astaxanthin. C. glutamicum grows fast to high cell densities [54] and, thus, is suitable for
production of carotenoids and other compounds that are stored within the cell. Here, C. glutamicum
was shown to produce β-carotene to about 12 mg¨ (g¨CDW)´1 within 24 h at a volumetric
productivity of about 3.4 mg¨L´1¨h´1. Growth and production of carotenoids by C. glutamicum
is monophasic and strains BETA4 and ASTA1 showed growth rates of 0.32 ˘ 0.01 h´1 and
0.29 ˘ 0.05 h´1, respectively. This is in contrast to biphasic growth/production of carotenoids
e.g., by the alga Haematococcus pluvialis [55]. As a consequence, the volumetric productivity for
β-carotene exceeds that reported for the industrially used microalga Dunaliella bardawil [56] or the
yeast Saccharomyces cerevisiae [57] by about a factor of three.
Combined expression of the genes coding for β-carotene ketolase and hydroxylase from
microorganisms that do not synthesize astaxanthin (B. aurantiaca and P. ananatis) in a β-carotene
producing C. glutamicum led to astaxanthin production. However, astaxanthin was not the main
carotenoid being produced. Since a balanced expression of the β-carotene ketolase and hydroxylase
genes are essential for an efficient astaxanthin production [48,58] we assumed that the activities of
the respective enzymes in the tested recombinants were not matched. Therefore, translation initiation
rates of the respective genes, crtW and crtZ, were varied in a combinatorial approach. However, a
strict correlation between TIR and production titers was not observed. As tendencies, the lower the
TIRs of both crtW and crtZ the lower were the canthaxanthin and astaxanthin titers, and the higher the
TIR of crtW the higher were astaxanthin titers (Figure 4).
In E. coli astaxanthin biosynthesis from β-carotene was reported to proceed more efficiently
via zeaxanthin rather than canthaxanthin since ketolated intermediates did not accumulate [48,58].
Both ketolase and hydroxylase compete for their substrates and accept β-carotene as well as
canthaxanthin and zeaxanthin, respectively, as substrates [59,60]. Independently induced expression
of crtZ from P. ananatis and crtW148 of Nostoc puntiforme PC73102 revealed that hydroxylation occurred
fast with β-carotene, echinenone, adonirubin, and canthaxanthin [58]. In their system, CrtW148 was
identified as the limiting step in conversion of zeaxanthin to astaxanthin [58]. Expression of crtZ
from P. ananatis in β-carotene producing C. glutamicum also yielded zeaxanthin [38] as did expression
of crtZ from F. pelagi in this study (data not shown). Varying expression levels of crtWBa and crtZPa
led to accumulation of zeaxanthin only if TIR for crtWBa was low (Figure 4). On the other hand,
canthaxanthin accumulated as intermediate typically if TIR of crtWBa was medium to high (Figure 4).
Canthaxanthin accumulation may be explained best by the assumption that β-carotene ketolase CrtW
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from B. aurantiaca did not accept the non-natural substrate zeaxanthin well. It is likely that astaxanthin
production by this approach was not only limited by an imperfect match between expression levels of
the β-carotene ketolase and hydroxylase genes, but rather by imperfect compatibility of the substrate
spectra of the chosen β-carotene ketolase and hydroxylase enzymes.
Consequently, crtW and crtZ genes from marine and non-marine bacteria known to synthesize
astaxanthin were examined in the second approach. Astaxanthin was produced in combinations
of CrtZ from the marine bacterium F. pelagi and CrtW from either F. pelagi, S. astaxanthinifaciens or
B. aurantiaca. F. pelagi was isolated from ocean surface water, an aerated environment at least transiently
exposed to high solar radiation [45]. It is hypothesized that carotenoids play an important role as
antioxidants for survival of F. pelagi under these conditions [50]. Analysis of the codon usage of crtW
and crtZ from F. pelagi revealed a good fit to the codon usage of C. glutamicum, which is in compliance
with the achieved astaxanthin titers of the recombinants. Co-expression of crtW from B. aurantiaca
and crtZ from F. pelagi led to comparable astaxanthin titers, but considerable β-carotene amounts
accumulated as side-product (Table 3), co-expression of crtW and crtZ from F. pelagi, instead, yielded
astaxanthin as major carotenoid (80%; Table 3).
As compared to β-carotene production of about 12 mg¨ (g¨CDW)´1 by the parent strain BETA4,
the astaxanthin titers were at least seven fold lower (Table 3). Thus, conversion of β-carotene to
astaxanthin is incomplete; however, other carotenoids besides canthaxanthin and residual β-carotene
did not accumulate to significant titers (data not shown and Table 3). The partial conversion of
β-carotene to astaxanthin may, thus, indicate that astaxanthin and/or intermediate(s) of its biosynthesis
are inhibitory. This is in line with our finding that overexpression of only crtW from F. pelagi
resulted in 0.5 mg¨ (g¨CDW)´1 canthaxanthin and 1.7 mg¨ (g¨CDW)´1 remaining β-carotene. Similarly,
overexpression of only crtZ yielded 1.1 mg¨ (g¨CDW)´1 zeaxanthin and 5.6 mg¨ (g¨CDW)´1 β-carotene
remained. Similarly, heterologous expression of crtW148 and crtZ in the β-carotene-producing E. coli
strain reduced the overall formation of carotenoids, indicating that the formation of the carotenoid
precursors were affected [58].
High product purities and titers are beneficial for downstream processing. The astaxanthin
producing C. glutamicum strain overexpressing crtW and crtZ from F. pelagi accumulated astaxanthin
(about 1.6 mg¨ (g¨CDW)´1) as major (about 80%) carotenoid. The fact that little β-carotene and
canthaxanthin accumulated (about 0.3 and 0.1 mg¨ (g¨CDW)´1, respectively) may be an important
advantage for downstream processing. Nevertheless, higher product purities can be obtained by
algae with 95% of total carotenoids being astaxanthin [58]. Purification of astaxanthin from the cell
walls of algae and red yeasts is challenging since algae like H. pluvialis accumulate astaxanthin
in response to stress and heavily walled cysts are formed in the red stage [55]. Extraction of
carotenoids from microalgae does not only require the removal of chlorophyll [61], but also efficient
cell breakage technology [55]. Ethoxyquin or other antioxidants are added to the cells in order to
minimize oxidation of the carotenoids during drying and cracking [58]. Because of laborious and
time-consuming extraction processes of astaxanthin from algal systems, its production by a prokaryotic
host, Escherichia coli, has emerged for substitution [62]. It has to be noted that H. pluvialis produces
esterified astaxanthin, which is more stable than the free form astaxanthin as it does not cross react
with proteins and e.g., lipoproteins [8], and which is incorporated easier by marine animals [63].
But hydrolysis of the ester narrows the bioavailability of astaxanthin e.g., to salmon [64]. The rigid cell
walls of the red yeast X. dendrorhous also requires cell breakage prior to astaxanthin extraction [65,66].
In contrast to that, a simple methanol-acetone extraction was sufficient to recover astaxanthin from
C. glutamicum cells at lab scale.
The volumetric productivities of up to about 0.4 mg¨L´1¨h´1 obtained in simple shaking flask
cultures by the recombinant C. glutamicum strains compare favorably with those reported for the
commercially used production hosts such as the green microalgae H. pluvialis [55,67] and the red
yeast Xanthophyllomyces dendrorhous (formerly Pfaffia rhodozyma) [6,68] under similar conditions as
well as recombinant E. coli [58]. Under optimal conditions, astaxanthin titers obtained e.g., with
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H. pluvialis are very high (up to about 40 mg¨ (g¨CDW)´1), but slow growth, biphasic growth
(green stage) and production (red stage) properties and the low final biomass concentrations reduce
the maximal volumetric productivity [55]. After the non-productive green phase (about 4 days),
the volumetric productivity for astaxanthin in the red stage is about 1 mg¨L´1¨h´1 and can be
maintained for extended periods [55]. Although astaxanthin product titers from red yeasts such as
X. dendrorhous are generally lower than from algae [69], higher growth rates and easier cultivation
conditions argue in favor of these yeasts [70]. After optimization of a glucose-based fed-batch process
a volumetric productivity of about 5 mg¨L´1¨h´1 was achieved [65,71]. Can it be envisioned that
comparably high volumetric productivities can be obtained using the recombinant C. glutamicum strains
described here? In pressurized high-cell-density fed-batch cultivations C. glutamicum grows to biomass
concentrations of about 220 g¨CDW¨L´1 within 24 h [54]. If this growth could be achieved with the
C. glutamicum strains accumulating astaxanthin to titers of about 1.6 mg¨ (g¨CDW)´1, theoretically
volumetric productivities of about 14 mg¨L´1¨h´1 may be achieved. Future work focused on process
intensification, however, needs to be performed in order to evaluate if scale-up to such high astaxanthin
volumetric productivities can be realized with C. glutamicum.
4. Materials and Methods
4.1. Bacterial Strains, Media and Growth Conditions
The strains and plasmids used in this work are listed in Table 4. C. glutamicum ATCC 13032 was
used as wild type (WT), for metabolic engineering the prophage-cured C. glutamicum MB001 [72] was
used as platform strain. Pre-cultivation of C. glutamicum strains was performed in LB medium or LB
with 50 mM glucose. For cultivation in CGXII medium [73], pre-cultivated cells were washed once with
CGXII medium without carbon source and inoculated to an initial OD600 of 1. Glucose was added as
carbon and energy source to a concentration of 100 mM. Standard cultivations of C. glutamicum
were performed at 30 ˝C in a volume of 50 mL in 500 mL flasks with two baffles shaking at
120 rpm. The OD600 was measured in dilutions using a Shimadzu UV-1202 spectrophotometer
(Duisburg, Germany). Alternatively, cultivations were performed in 1 mL volume in micro-titerplates
at 1100 rpm at 30 ˝C using Biolector® micro fermentation system (m2p-labs GmbH, Baesweiler,
Germany). For cloning, E. coli DH5α was used as host and cultivated in LB medium at 37 ˝C.
When appropriate, kanamycin, tetracycline or spectinomycin was added to concentrations of 25, 5, and
100 µg¨mL´1, respectively. Gene expression was induced by addition of 1 mM IPTG, at inoculation of
the main culture.
Table 4. Strains and plasmids used in this study.
Strain; Plasmid Relevant Characteristics Reference
C. glutamicum Strains
WT Wild type, ATCC 13032 [74]
MB001 prophage cured, genome reduced ATCC 13032 [72]
LYC3 crtYeYfEb deletion mutant of C. glutamicum MB001 [42]
LYC4
LYC3 derivative with an artificial operon containing crtE, crtB, and crtI under
control of the Ptuf promoter integrated into the chromosome
this work
LYC5 LYC4 derivative with dxs under control of the Ptuf promoter integratedinto the chromosome this work
BETA1 LYC5 derivative (pEKEx3_ crtYPa) this work
BETA2 LYC5 derivative (pSH1_ crtYPa) this work
BETA3 LYC5 derivative with crtYPa under control of the Ptuf promoter integratedinto the chromosome this work
BETA4 cg0725 deletion mutant of C. glutamicum BETA3 this work
ASTA1 C. glutamicum BETA4 carrying pSH1_crtW1Fp and pEC-XT_crtZFp this work
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Table 4. Cont.
Strain; Plasmid Relevant Characteristics Reference
Other Strains
E. coli DH5α F- thi-1 endA1 hsdr17(r-, m-) supE44 ∆lacU169 (Φ80lacZ∆M15) recA1 gyrA96 [75]
Pantoea ananatis Wild type, ATCC 33244, DSM 17873, Z96081 [76]
Brevundimonas aurantiaca Wild type, ATCC 15266, DSM 4731, NR028889 [77]
Brevundimonas bacteroides Wild type, ATCC 15254, DSM 4726, AJ227782 [49]
Brevundimonas vesicularis Wild type, ATCC 11426, DSM 7226, LN681560 [78]
Fulvimarina pelagi Wild type, ATCC BAA-666, DSM 15513, AY178860 [50]
Sphingomonas astaxanthinifaciens Wild type, NBRC 102146, DSM 22298, AB277583 [52]
Plasmids
pEC-XT99A (pEC-XT) TetR, PtrclacIq, pGA1 oriVCg, C. glutamicum/E. coli expression shuttle vector [79]
pEC-XT_crtZBb
pEC-XT derivative for IPTG-inducible expression of crtZ from B. bacteroides
containing an artificial ribosome binding site this work
pEC-XT_crtZBv
pEC-XT derivative for IPTG-inducible expression of crtZ from B. vesicularis
containing an artificial ribosome binding site this work
pEC-XT_crtZFp
pEC-XT derivative for IPTG-inducible expression of crtZ from F. pelagi containing
an artificial ribosome binding site this work
pEC-XT_crtZSa
pEC-XT derivative for IPTG-inducible expression of crtZ from S. astaxanthinifaciens
containing an artificial ribosome binding site this work
pEKEx3 SpecR, PtaclacIq, pBL1 oriVCg, C. glutamicum/E. coli expression shuttle vector [80]
pEKEx3_crtYPa
pEKEx3 derivative for IPTG-inducible expression of crtY from P. ananatis
containing an artificial ribosome binding site this work
pVWEx1 KmR, PtaclacIq, pHM519 oriVCg, C. glutamicum/E. coli expression shuttle vector [81]
pSH1 KmR, Ptuf, pHM519 oriVCg, C. glutamicum/E. coli expression shuttle vector this work
pSH1_crtYPa
pSH1 derivative for constitutive expression of crtY from P. ananatis containing an
artificial ribosome binding site this work
pSH1_crtWBa_crtZPa
pSH1 derivative for constitutive expression of crtW from B. aurantiaca and crtZ
from P. ananatis containing artificial ribosome binding sites this work
pSH1_crtWBa
pSH1 derivative for constitutive expression of crtW from B. aurantiaca containing
an artificial ribosome binding site this work
pSH1_crtWBb
pSH1 derivative for constitutive expression of crtW from B. bacteroides containing
an artificial ribosome binding site this work
pSH1_crtW1Bv
pSH1 derivative for constitutive expression of crtW from B. vesicularis containing
an artificial ribosome binding site this work
pSH1_crtW2Bv
pSH1 derivative for constitutive expression of crtW from B. vesicularis containing
an artificial ribosome binding site this work
pSH1_crtW1Fp
pSH1 derivative for constitutive expression of crtW from F. pelagi containing an
artificial ribosome binding site this work
pSH1_crtW2Fp
pSH1 derivative for constitutive expression of crtW from F. pelagi containing an
artificial ribosome binding site this work
pSH1_crtW3Fp
pSH1 derivative for constitutive expression of crtW from F. pelagi containing an
artificial ribosome binding site this work
pSH1_crtWSa
pSH1 derivative for constitutive expression of crtW from S. astaxanthinifaciens
containing an artificial ribosome binding site this work
pK19mobsacB Km
R; E. coli/C. glutamicum shuttle vector for construction of insertion and deletion
mutants in C. glutamicum (pK18 oriVEc sacB lacZα)
[82]
pK19mobsacB-cg0725 pK19mobsacB with a cg0725 deletion construct -
pK19mobsacB-Ptuf-dxs
pK19mobsacB derivative with a tuf promoter region (200 bp upstream of the coding
sequence of the tuf gene(cg0587) construct for the promoter exchange of dxs [42]
pK19mobsacB-IntcrtEBI
pK19mobsacB derivative containing the artificial operon crtE_crtBI under the
control of the Ptuf promoter with an addition ribosome binding site in front of crtB
for integration in the cgp2 cured region of C. glutamicum MB001
this work
pVWEx1-crtEBI pVWEx1 derivative for IPTG-inducible expression of crtE, crtB and crtI fromC. glutamicum containing artificial ribosome binding sites in front of crtE and crtBI [38]
pK19mobsacB-IntcrtY
pK19mobsacB derivative containing crtY of Pantoea ananatis under the control of the
Ptuf promoter for integration in the cgp1 cured region of C. glutamicum MB001
this work
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4.2. Recombinant DNA Work
Plasmids were constructed in E. coli DH5α from PCR-generated fragments (All-in HiFi,
highQu, Kraichtal, Germany) and isolated with the Plasmid GeneJET Miniprep kit (Thermo Fisher
Scientific, Schwerte, Germany). Oligonucleotides used in this study were obtained from Metabion
(Planegg/Steinkirchen, Germany) and are listed in Table 5. Standard reactions like restriction, and
PCR were performed as described previously [83]. Besides cloning by restriction, Gibson assembly
was applied for the construction of plasmids [44]. If applicable, PCR products were purified using
the PCR clean-up and gel extraction kit (Macherey-Nagel, Düren, Germany). For transformation of
E. coli DH5α, the RbCl method was used and C. glutamicum was transformed via electroporation [84]
at 2.5 kV, 200 Ω, and 25 µF. All cloned DNA fragments were confirmed by sequencing.
Table 5. Oligonucleotides used in this study.
Oligonucleotide Sequence (5'Ñ3')
N1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGACCGCCGCCGTCGCCGAG
N2 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGGTGACCGCCGCCGTCGCCGAG
N3 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCATGACCGCCGCCGTCGCCGAG
N4 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCGTGACCGCCGCCGTCGCCGAG
N5 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCATGACCGCCGCCGTCGCCGAG
N6 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCGTGACCGCCGCCGTCGCCGAG
N7 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCTTCAGATGACCGCCGCCGTCGCCGAG
N8 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCTTCAGGTGACCGCCGCCGTCGCCGAG
N9 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCTTCATGACCGCCGCCGTCGCCGAG
N10 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCTTCGTGACCGCCGCCGTCGCCGAG
N11 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCATGACCGCCGCCGTCGCCGAG
N12 CATGCCTGCAGGTCGACTCTAGAGGAAAGAAGGCCCGTGACCGCCGCCGTCGCCGAG
N13 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCTTCAGATGACCGCCGCCGTCGCCGAG
N14 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCTTCAGGTGACCGCCGCCGTCGCCGAG
N15 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCTTCATGACCGCCGCCGTCGCCGAG
N16 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCTTCGTGACCGCCGCCGTCGCCGAG
N17 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCATGACCGCCGCCGTCGCCGAG
N18 CATGCCTGCAGGTCGACTCTAGAGGAATGGAGGCCCGTGACCGCCGCCGTCGCCGAG
N19 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCTTCAGATGACCGCCGCCGTCGCCGAG
N20 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCTTCAGGTGACCGCCGCCGTCGCCGAG
N21 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCTTCATGACCGCCGCCGTCGCCGAG
N22 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCTTCGTGACCGCCGCCGTCGCCGAG
N23 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCATGACCGCCGCCGTCGCCGAG
N24 CATGCCTGCAGGTCGACTCTAGAGGAATGAAGGCCCGTGACCGCCGCCGTCGCCGAG
N25 AACTGCCACACGAACGAAAGGAGGCCCTTCAGATGTTGTGGATTTGGAATGCCCTGATC
N26 AACTGCCACACGAACGAAAGGAGGCCCTTCAGGTGTTGTGGATTTGGAATGCCCTGATC
N27 AACTGCCACACGAACGAAAGGAGGCCCTTCATGTTGTGGATTTGGAATGCCCTGATC
N28 AACTGCCACACGAACGAAAGGAGGCCCTTCGTGTTGTGGATTTGGAATGCCCTGATC
N29 AACTGCCACACGAACGAAAGGAGGCCCATGTTGTGGATTTGGAATGCCCTGATC
N30 AACTGCCACACGAACGAAAGGAGGCCCGTGTTGTGGATTTGGAATGCCCTGATC
N31 AACTGCCACACGAACGAAAGAAGGCCCTTCAGATGTTGTGGATTTGGAATGCCCTGATC
N32 AACTGCCACACGAACGAAAGAAGGCCCTTCAGGTGTTGTGGATTTGGAATGCCCTGATC
N33 AACTGCCACACGAACGAAAGAAGGCCCTTCATGTTGTGGATTTGGAATGCCCTGATC
N34 AACTGCCACACGAACGAAAGAAGGCCCTTCGTGTTGTGGATTTGGAATGCCCTGATC
N35 AACTGCCACACGAACGAAAGAAGGCCCATGTTGTGGATTTGGAATGCCCTGATC
N36 AACTGCCACACGAACGAAAGAAGGCCCGTGTTGTGGATTTGGAATGCCCTGATC
N37 AACTGCCACACGAACGAATGGAGGCCCTTCAGATGTTGTGGATTTGGAATGCCCTGATC
N38 AACTGCCACACGAACGAATGGAGGCCCTTCAGGTGTTGTGGATTTGGAATGCCCTGATC
N39 AACTGCCACACGAACGAATGGAGGCCCTTCATGTTGTGGATTTGGAATGCCCTGATC
N40 AACTGCCACACGAACGAATGGAGGCCCTTCGTGTTGTGGATTTGGAATGCCCTGATC
N41 AACTGCCACACGAACGAATGGAGGCCCATGTTGTGGATTTGGAATGCCCTGATC
N42 AACTGCCACACGAACGAATGGAGGCCCGTGTTGTGGATTTGGAATGCCCTGATC
N43 AACTGCCACACGAACGAATGAAGGCCCTTCAGATGTTGTGGATTTGGAATGCCCTGATC
N44 AACTGCCACACGAACGAATGAAGGCCCTTCAGGTGTTGTGGATTTGGAATGCCCTGATC
N45 AACTGCCACACGAACGAATGAAGGCCCTTCATGTTGTGGATTTGGAATGCCCTGATC
N46 AACTGCCACACGAACGAATGAAGGCCCTTCGTGTTGTGGATTTGGAATGCCCTGATC
N47 AACTGCCACACGAACGAATGAAGGCCCATGTTGTGGATTTGGAATGCCCTGATC
N48 AACTGCCACACGAACGAATGAAGGCCCGTGTTGTGGATTTGGAATGCCCTGATC
N49 GTTCGTGTGGCAGTTTTAGTGGTGGTGGTGGTGGTGAGACTCGCCGCGCCACAGACG
N50 ATTCGAGCTCGGTACCCGGGGATCTTACTTTTCGAACTGTGGGTGGGACCACTTCCCGGATGCGGGCTC
BaW1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGACCGCCGCCGTCGCCGAG
BaW2 CGGTACCCGGGGATCTCAAGACTCGCCGCGCCAC
BbW1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGACGCGGGAACGCCA
BbW2 ATTCGAGCTCGGTACCCGGGGATCTTAGAGACGTTCGCTACGC
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Table 5. Cont.
Oligonucleotide Sequence (5'Ñ3')
BbZ1 ATGGAATTCGAGCTCGGTACCCGGGGAAAGGAGGCCCTTCAGATGACGATCGTCTGGTTCAC
BbZ2 GCATGCCTGCAGGTCGACTCTAGAGGATCTTACTCGGCCGGGATGTCC
BvW1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGGGGCAAGCGAACAG
BvW2 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGCGGCAAGCGAACAG
BvW3 ATTCGAGCTCGGTACCCGGGGATCCTAGCTGAACAAACTCCACCAG
BvZ1 ATGGAATTCGAGCTCGGTACCCGGGGAAAGGAGGCCCTTCAGATGTCCTGGCCGACGATG
BvZ2 GCATGCCTGCAGGTCGACTCTAGAGGATCTTAGGCGCCGTTGCTGGAT
FpW1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGACCCTCAGCCCAACCTC
FpW2 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGAGACCCTACCAAACGACG
FpW3 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGCATGGTTCGCTGGC
FpW4 ATTCGAGCTCGGTACCCGGGGATCTTAGGACTGGCGAGTATGCG
FpZ1 ATGGAATTCGAGCTCGGTACCCGGGGAAAGGAGGCCCTTCAGATGACGATCTGGACTCTCTACTAC
FpZ2 GCATGCCTGCAGGTCGACTCTAGAGGATCTTACCGAACCGGCGCGT
SaW1 CATGCCTGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGGCCCCCATGCTCAGTG
SaW2 ATTCGAGCTCGGTACCCGGGGATCTTAGGCGGGAAGCGCAAG
SaZ1 ATGGAATTCGAGCTCGGTACCCGGGGAAAGGAGGCCCTTCAGATGTCCTGGCCTGCCG
SaZ2 GCATGCCTGCAGGTCGACTCTAGAGGATCTTAGGCCCGCTCCTCGTG
pSH1 fw ACCGGCTCCAGATTTATCAG
pVWEx/ pSH1 rv ATCTTCTCTCATCCGCCA
pEC-XT fw AATACGCAAACCGCCTCTCC
pEC-XT rv TACTGCCGCCAGGCAAATTC
pV_Ptuf -fw CGGAATCTTGCACGCCCTTGGCCGTTACCCTGCGAATG
pV_Ptuf -rv CTGCAGGCATGCAAGCTTTGTATGTCCTCCTGGACTTC
pV1-fw GAAGTCCAGGAGGACATACAAAGCTTGCATGCCTGCAG
pV6962-rv CATTCGCAGGGTAACGGCCAAGGGCGTGCAAGATTCCG
cg0725-A GCAGGTCGACTCTAGAGGATCCCCGCGCGAAGATTTGATGGG
cg0725-B CCCATCCACCCCGGGTAAACATTCCTGCATATTCAGCATAGTAATC
cg0725-C TGTTTACCCGGGGTGGATGGGTCCCTTAATAATGCACCATGGC
cg0725-D CCAGTGAATTCGAGCTCGGTACCCCTTGTCACCACAGCACTACT
cg0725-E GCGCGAAGATTTGATGGG
cg0725-F ACTTGTCACCACAGCACTAC
crtY-Int1 GCAGGTCGACTCTAGAGGATCCCCCAGTGAAGGATCGGTGCG
crtY-Int2 CATTCGCAGGGTAACGGCCACCTATCTGCTGGCCGGTG
crtY-Int3 CACCGGCCAGCAGATAGGTGGCCGTTACCCTGCGAATG
crtY-Int4 CAGATCATAATGCGGTTGCATTGTATGTCCTCCTGGACTTC
crtY-Int5 GAAGTCCAGGAGGACATACAATGCAACCGCATTATGATCTG
crtY-Int6 TCTTACTACTTGCGCTAGGTACAGTTAACGATGAGTCGTCATAATGG
crtY-Int7 CCATTATGACGACTCATCGTTAACTGTACCTAGCGCAAGTAGTAAGA
crtY-Int8 CCAGTGAATTCGAGCTCGGTACCCCTGCTCATCCTTCAACAACGT
cgp1-E GTGGTGCTCGAGAACATAAG
cgp1-F CGGTCACCCGTAACAATCAG
crtEBI-Int1 GCAGGTCGACTCTAGAGGATCCCCGTGCTTCGCATCGTCTATGTC
crtEBI-Int2 CATTCGCAGGGTAACGGCCAATAGTTGGGGGAATTTATAAGGATTTG
crtEBI-Int3 CAAATCCTTATAAATTCCCCCAACTATTGGCCGTTACCCTGCGAATG
crtEBI-Int4 GATTGTCATGCCATTGTCCATTGTATGTCCTCCTGGACTTC
crtEBI-Int5 GAAGTCCAGGAGGACATACAATGGACAATGGCATGACAATC
crtEBI-Int6 CTAATGGACGGTGAAGTATCATTTATGTTAATGATCGTATGAGGTCTTTTGAG
crtEBI-Int7 CTCAAAAGACCTCATACGATCATTAACATAAATGATACTTCACCGTCCATTAG
crtEBI-Int8 CCAGTGAATTCGAGCTCGGTACCCCGCCGTATGTAACAAGATTTG
Cgp2-E TCGCACCATCTACGACAACC
Cgp2-F CTACGAAGCTGACGCCGAAG
Sequence in bold: artificial ribosome binding site; sequence underlined: tag site; sequence in italics: linker
sequence for hybridization.
4.3. Construction of Expression Vector pSH1
The plasmid pSH1 was constructed based on the expression vector pVWEx1 [81]. The backbone of
pSH1 was amplified from pVWEx1 omitting the lacIq and Ptac region using the oligonucleotides pV1-fw
and pV6962-rv (Table 5) with All-in HiFi polymerase (highQu, Kraichtal, Germany). The promoter
of the C. glutamicum tuf gene (cg0587) was amplified using the primers pV_Ptuf-fw and pV_Ptuf-rv
(Table 5). Both fragments were assembled using the Gibson method [44]. Vector sequence was
confirmed via sequencing to exclude mutations.
4.4. Deletion and Exchenge Mutagenesis in the Genome of C. glutamicum
For targeted deletion of cg0725, which encodes a transcriptional regulator and is part of the
carotenogenesis gene cluster of C. glutamicum, the suicide vector pK19mobsacB was used [82].
Genomic regions flanking cg0725 were amplified from genomic DNA of C. glutamicum WT using primer
pairs cg0725-A/B and cg0725-C/D (Table 5), respectively. Subsequently the purified PCR products
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were linked by crossover PCR using the primer pair cg0725-A/D (Table 5). The resulting amplificate
was cloned into pK19mobsacB resulting in the construction of deletion vector pK19mobsacB-cg0725
(Table 4). Deletion of cg0725 via two-step homologous recombination as well as the selection for the first
and second recombination events were carried out as described previously [85]. Successful removal of
cg0725 was verified by PCR analysis of the constructed mutant using primer pair cg0725-E/F (Table 5).
The integration of the synthetic operon crtEBI and the lycopene cyclase gene of
Pantoea ananatis crtY, respectively, was conducted by using the suicide vector pK19mobsacB [82].
Operon crtEBI consists of the carotenogenic genes crtE (cg0723), crtB (cg0721) and crtI (cg0720) and
was amplified from the expression vector pVWEx1-crtEBI [38] using the oligonucleotides crtEBI-Int5
and crtEBI-Int6. The Ptuf promoter region was amplified using the oligonucleotides crtEBI-Int3/4
or crtY-Int3/4, respectively. Genomic regions flanking the selected insertion region were amplified
from genomic DNA of C. glutamicum MB001 using primer pairs crtEBI-Int1/2 and crtEBI-Int7/8 for
integration in the cgp2 cured region in the case of the crtEBI operon, or crtY-Int1/2 and crtY-Int7/8
for integration of crtY in the CGP1 cured region (Table 5), respectively. CrtY was amplified from
genomic DNA of P. ananatis using the primer pair crtY-Int5/6. The purified PCR products were
directly combined together with the plasmid by Gibson assembly [44]. The final assembly of the
insert with linearized pK19mobsacB led to the construction of the respective integration vectors
pK19mobsacB-IntcrtEBI and pK19mobsacB-IntcrtY (Table 4). The following integration of the operon by
two-step homologous recombination was performed according to the deletion of genes. The integration
in the cgp1 or cgp2 region was verified by PCR using the primers cgp1-E/F and cgp2-E/F, respectively.
The plasmid pK19mobsacB-Ptuf-dxs was constructed to replace the native dxs promoter with the tuf
promoter region from C. glutamicum WT as described earlier [42]. The promoter exchange was verified
by PCR using the primers dxs E and 33, and sequencing of the PCR product.
4.5. Combinatorial Gene Assembly, Library Construction and Overexpression of Carotenogenic Genes
The combinatorial assembly of genes crtWBa and crtZPa was performed with Gibson Assembly [44].
The crtW gene was amplified from the genomic DNA of Brevundimonas aurantiaca in a one-pot-PCR
containing an equimolar mixture of forward primers (N1-N24) and a reverse primer (N49) (Table 5).
The crtZ gene was amplified from the genomic DNA of Pantoea ananatis in a one-pot-PCR containing an
equimolar mixture of forward primers (N25-N48) and a reverse primer (N50) (Table 5). PCR products
of both genes were gel-extracted (Macherey-Nagel) and cloned in BamHI-restricted pSH1 applying
Gibson Assembly. The transformation of E. coli DH5α was done as described above. 1/10 of the
transformed cells were plated on selective agar plates for colony number calculation while 9/10 of the
transformants were grown in selective liquid medium for plasmid isolation. Isolated plasmids were
used for transformation of C. glutamicum strain BETA1.
Plasmids harboring a carotenogenic gene (general abbreviation crt), pECXT99A_crt, pEKEX3_crt
or pVWEx1_crt allowed an IPTG-inducible overexpression of crt. The vector pSH1 expressed
crt constitutively under the tuf -promoter (Ptuf). The plasmids were constructed on the basis of
pECXT99A [79] pEKEx3 [80] or pVWEx1 [81], respectively. Amplification of crt was achieved by
polymerase chain reaction (PCR) from genomic DNA of C. glutamicum ATCC 13032, P. ananatis,
B. aurantiaca, B. bacteroides, B. vesicularis, F. pelagi, and S. astaxanthinifaciens, respectively, that was
prepared as described [86] using the respective primers (Table 5). The amplified products were cloned
into the BamHI restricted pEC-XT99A, pEKEx3, pVWEx1 or pSH1 plasmid DNA by Gibson assembly.
4.6. Extraction and Quantification of Carotenoids
For extracting carotenoids from C. glutamicum, 1 mL of the culture was harvested by centrifugation
for 7 min at 14,000 rpm. Carotenoid pigments were extracted with 800 µL methanol:acetone (7:3)
containing 0.05% BHT at 60 ˝C for 15 min with careful vortexing every 5 min. Cell debris was
spun down for 7 min at 14,000 rpm and the supernatant was used for high performance liquid
chromatography (HPLC) analysis. For HPLC the Agilent 1200 series system (Agilent Technologies
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Sales & Services GmbH & Co. KG, Waldbronn, Germany) was used. The UV/visible (Vis) spectrum
was recorded with a diode array detector (DAD). The quantification of carotenoids was performed by
the integration of the extracted wavelength chromatogram at λmax 470 nm for every maximum and
by the analysis of the appropriate UV/Vis profiles. Standard calibration curves were generated with
lycopene (Sigma-Aldrich), β-carotene (Sigma-Aldrich), canthaxanthin (Sigma-Aldrich), zeaxanthin
(Sigma-Aldrich) and astaxanthin (Sigma-Aldrich) to quantify carotenoid titers. All standards were
dissolved in chloroform according to their solubility and diluted in methanol:acetone (7:3) containing
0.05% BHT.
As column system, a precolumn (10 ˆ 4 mm MultoHigh 100 RP18-5, CS Chromatographie
Service GmbH, Langerwehe, Germany) and a main column (ProntoSIL 200–5 C30, 250 ˆ 4 mm, CS
Chromatographie Service GmbH) were used. The HPLC protocol ensured a gradient elution for 10 min
and a mobile phase composition of (A) methanol and (B) methanol/methyl tert-butyl ether/ethyl
acetate (5:4:1) starting from 10% to 100% of eluent B, followed by 20 min of isocratic elution with
100% B. After that, the eluent composition was set back to 10% B for 3 min. The injection volume was
100 µL and the flow rate was kept constant at 1.4 mL/min.
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